Figure 6.

Indirect enzyme-linked immunosorbent assay (ELISA) results for the determination of the affinity of vedolizumab (A), infliximab (B), adalimumab (C) and ustekinumab (D) conjugates to their target. Each panel (A–D) shows overlayed results of one antibody’s reference standard and conjugates of that antibody to 3 different dyes. Serially diluted binding curves were compared to an unmodified reference on the same plate. Affinity was calculated as the ratio between the EC50 values for reference and sample curves. Comparable binding affinities were shown for all conjugates except infliximab-800CW, infliximab-680LT and ustekinumab-680LT